EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer

Vincent D D'Andrea iD, Christopher J Magnani, John Ernandez, Joaquim Bellmunt, Matthew Mossanen, Timothy N Clinton, Filipe L F Carvalho, Kent W Mouw

Current Urology Reports · 2025-12 · 26 (1)

DOI: 10.1007/s11934-024-01242-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Urology Reports, online erschienen am 09.10.2024. Verfasst von Vincent D D'Andrea und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brigham & Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. vdandrea@bwh.harvard.edu. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which integrate DDR inhibitors with standard chemotherapy and immunotherapy. RECENT FINDINGS: Noteworthy findings include the ATLANTIS trial, which demonstrated prolonged progression-free survival (PFS) in DDR biomarker-selected patients using PARP inhibitors as maintenance after standard chemotherapy. Trials such as BAYOU, which combined immunotherapy with PARP inhibition, similarly suggested a potential therapeutic benefit in DDR biomarker-selected patients with bladder cancer. Efforts to develop bladder-sparing treatment regimens based on DDR-associated mutational profiles, such as the RETAIN and HCRN 16-257 trials, have had mixed outcomes to date. There are now ongoing efforts to combine DDR inhibitors with the newest bladder cancer therapies, such as antibody-drug conjugates. This review highlights the most recent advances in targeting DNA repair deficiency in the evolving treatment landscape of bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsHumansPoly(ADP-ribose) Polymerase InhibitorsDNA Repair-Deficiency DisordersDNA RepairImmunotherapy

Stichwörter der Autor:innen

Bladder cancerChemotherapyClinic TrialsDNA RepairPARP Inhibitors

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Brigham & Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. vdandrea@bwh.harvard.edu.
  • Brigham & Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Vincent D D'Andrea

Zitieren

APA

D'Andrea, V. D., Magnani, C. J., Ernandez, J., Bellmunt, J., Mossanen, M., Clinton, T. N., Carvalho, F. L. F., & Mouw, K. W. (2025). Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. Current Urology Reports, 26(1). https://doi.org/10.1007/s11934-024-01242-4

Vancouver

D'Andrea VD, Magnani CJ, Ernandez J, Bellmunt J, Mossanen M, Clinton TN, et al. Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer. Current Urology Reports. 2025;26(1). doi:10.1007/s11934-024-01242-4

BibTeX
@article{DAndrea2025,
  author = {D'Andrea, Vincent D and Magnani, Christopher J and Ernandez, John and Bellmunt, Joaquim and Mossanen, Matthew and Clinton, Timothy N and Carvalho, Filipe L F and Mouw, Kent W},
  title = {Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer},
  journal = {Current Urology Reports},
  year = {2025},
  volume = {26},
  number = {1},
  doi = {10.1007/s11934-024-01242-4}
}
Kostenlos starten →